Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. principal accounting officer Marc Cobo reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 125 shares of Common Stock to cover his tax obligations, rather than selling them in the open market. Following this withholding, Cobo directly holds 5,306 shares of Common Stock.
BridgeBio Oncology Therapeutics, Inc. reported a routine insider equity event for COO & Principal Financial Officer Elmelech Idan. The company withheld 343 shares of Common Stock at $7.80 per share to cover his tax obligations tied to vesting restricted stock units. This was a tax-withholding disposition, not an open-market trade, and reflects how part of his equity award was used to pay taxes. After this withholding, Idan directly holds 14,495 shares of the company’s common stock.
BridgeBio Oncology Therapeutics, Inc. Chief Medical & Development Officer Ben Yong had 1,047 shares of common stock withheld on July 1, 2026 to cover tax obligations tied to vesting restricted stock units. This was an automatic tax-withholding disposition at $7.80 per share, not an open-market trade. After this transaction, Yong directly owned 44,576 shares of BridgeBio Oncology common stock.
BridgeBio Oncology Therapeutics, Inc. reported that President and CEO Pedro Beltran had 1,047 shares of Common Stock withheld by the company at $7.80 per share to cover tax obligations from vesting restricted stock units. After this withholding, he directly holds 44,576 shares of Common Stock. This was a tax-withholding disposition, not an open-market sale.
BridgeBio Oncology Therapeutics, Inc. received an Amendment No. 3 to a Schedule 13D from Cormorant-affiliated investors led by Bihua Chen. The reporting group now shows beneficial ownership of 17,878,594 shares of common stock, or 22.32% of the company’s 80,107,104 shares outstanding as of the latest 10-Q.
The update reflects a pro rata distribution of 4,528,186 shares by Helix Holdings II LLC to its members, after which Helix holds no shares. Fund III, Fund V, and the Master Fund each received additional shares and entered a joinder to the existing lock-up agreement covering these distributed shares. The filing also notes that director Bihua Chen was granted 31,675 stock options at an exercise price of $7.73, which remain unvested.
BridgeBio Oncology Therapeutics, Inc. director and 10% owner Bihua Chen reported indirect ownership changes tied to a restructuring among investment vehicles associated with Helix Holdings II LLC, the Sponsor. The filing shows a pro rata distribution of 4,528,186 common shares from the Sponsor to its members for no consideration.
According to the footnotes, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund V, LP, and Cormorant Global Healthcare Master Fund, LP each received shares in this pro rata distribution, and Cormorant Private Healthcare Fund IV, LP is also managed by the same investment manager. Post-transaction indirect holdings include 1,905,046 shares via Fund IV and 6,083,221 shares via the Master Fund. The transactions are classified as "other" (code J), reflect internal allocations with no open-market buying or selling, and include disclaimers that Ms. Chen and the funds only beneficially own securities to the extent of their pecuniary interests.
BridgeBio Oncology Therapeutics, Inc. is registering 63,054,549 shares of Common Stock for resale by selling securityholders under Prospectus Supplement No. 8 dated June 22, 2026.
The supplement attaches a Form 8-K reporting governance items from the June 16, 2026 annual meeting, including director election results, ratification of Deloitte & Touche LLP, and that 80,112,725 shares were entitled to vote at the meeting with 48,344,441 shares present or represented by valid proxy. The supplement updates and supplements the Prospectus dated September 10, 2025.
BridgeBio Oncology Therapeutics, Inc. reported results from its June 16, 2026 Annual Meeting of Stockholders and a board change. Director Michelle Doig resigned from the Board at the end of her term as a Class I director, and the company stated her resignation was not due to any disagreement regarding operations, policies or practices.
Stockholders elected two Class I directors. Peter Lebowitz received 31,822,504 votes for and 3,372 withheld. Frank P. McCormick received 25,654,119 votes for and 6,171,757 withheld. The company reported 2,713,439 broker non-votes and 13,805,126 no votes on this proposal.
Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,535,875 votes for, 3,440 against and no abstentions, and 13,805,126 no votes reported for this proposal.
BridgeBio Oncology Therapeutics director Praveen P. Tipirneni received a stock option grant for 31,675 shares of Common Stock. The option has an exercise price of $7.73 per share and expires on June 15, 2036. It vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds options for 31,675 shares directly, with no open-market buying or selling reported in this filing.
BridgeBio Oncology Therapeutics director Frank McCormick received a new stock option grant. He was awarded options for 31,675 shares of common stock at an exercise price of $7.73 per share. These options were granted at no upfront cost and are held as a direct ownership position.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, as long as he continues serving the company through that date. Following this grant, his reported derivative holdings from this award total 31,675 underlying shares.